In this context, TGF-beta pathway blockade through TGF-beta receptor (TGFBR)-1 inhibition or TGF-beta blocking antibody enabled T cells infiltration into the tumor, restoring the anti-tumor immunity induced by the anti-PD-L1 antibody in BC and CRC pre-clinical models (Mariathasan et al., 2018; Tauriello et al., 2018). Here, TGFBR1 is linked to neoplasm.